NMF
  • Menu Canvas
    • NMF
      • Nikki Mitchell Foundation
      • Nikki Mitchell
        • Bridge of Wings Flight
        • Documentary
      • Financials and Board
      • Contact Us
    • Programs
      • Bridge of Wings
      • Hope Suite Hope
    • Pancreatic Cancer
      • Statistics & Risk Factors
      • Research & Detection
        • Seed Grant Awardees
    • Inspiration
      • Volunteers
      • Warriors
    • Events
      • Previous Event Photos
    • News
    • Donate
    • NMF
      • Nikki Mitchell Foundation
      • Financials and Board
      • Nikki Mitchell
      • Contact
    • Pancreatic Cancer
      • Statistics & Risk Factors
      • Research & Detection
    • Programs
      • Bridge of Wings
      • Hope Suite Hope
    • Inspiration
      • Warriors
      • Volunteers
    • Events
    • News
NMF
  • NMF
    • Nikki Mitchell Foundation
    • Nikki Mitchell
      • Bridge of Wings Flight
      • Documentary
    • Financials and Board
    • Contact Us
  • Programs
    • Bridge of Wings
    • Hope Suite Hope
  • Pancreatic Cancer
    • Statistics & Risk Factors
    • Research & Detection
      • Seed Grant Awardees
  • Inspiration
    • Volunteers
    • Warriors
  • Events
    • Previous Event Photos
  • News
  • Donate

After Neoadjuvant Therapy, Imaging No Longer Provides a Clear Answer

After Neoadjuvant Therapy, Imaging No Longer Provides a Clear Answer

Christa Bowles
February 11, 2019
Blog, Uncategorized

The following summary comes the article by Dr. Cristina Ferrone and was published in the International Journal of Radiation Oncology, Biology, Physics. The full article can be found here.

Image credit: Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12-7.

Patients with a presumed diagnosis of pancreatic cancer are initially evaluated by radiological imaging (Pancreas protocol CT-scan). Imaging provides a great deal of information regarding the tumor including tumor size, involvement of nearby blood vessels and organs, and distant spread of disease. Patients with tumors that involve nearby blood vessels may not be a candidate for a surgery-first approach and have been shown to benefit from upfront chemotherapy followed by potential surgical resection (see October blog post, “Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy” for more information on vessel involvement).

Given the improvements in chemotherapy a majority of patients with pancreatic cancer are now managed via a neoadjuvant-first approach even when diagnosed at a resectable stage, given that systemic disease dictates long term outcomes. With this change in practice, a majority of patients initially receive chemo/chemoradiation therapy followed by a repeat scan (re-staging scan), and a potential surgical resection. Recently, it has become evident that post-neoadjuvant CT scans might not provide accurate assessment of disease. At Massachusetts General Hospital in Boston, MA, researchers have theorized that preoperative chemoradiation may cause tumors to appear worse on CT scans than before therapy. With this in mind, this group sought to find patients who received neoadjuvant therapy and had unfavorable imaging after the neoadjuvant therapy, but did have a good performance status and a decrease in pancreatic cancer tumor markers (CA19-9). These patients were taken to the operating room for surgical exploration to evaluate the true extent of disease. Promisingly, 92% of the first 40 patients underwent R0 resection margins, meaning there was no tumor seen at the resection plane (see August blog post, “The Importance of Resection Margin Status in Pancreatic Surgery” for more information on resection margins). What was observed on the CT-scans of these patients was most likely dead tissue with scarring that was mimicking living tumor.

In conclusion, patients with good performance status and decreasing tumor markers after neoadjuvant therapy should be considered for surgical exploration, even if CT scans demonstrate persistent tumor.

A special thanks for this summary by Michael Wright, Department of Surgery, Johns Hopkins School of Medicine and to Dr. Ammar Javed for his support.

Tags: Biology International Journal of Radiation Oncology Neoadjuvant Therapy pancreatic cancer Physics
Previous Story
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Next Story
Oral Microbiota Mouth Off in Cystic Pancreatic Tumors

Related Articles

Your Dollars at Work

Nikki Mitchell Foundation is a relatively young non-profit. In the...

2021 Impact Report

2021 was full of challenges for everyone, but the Nikki...

Recent Posts

  • Music Leader Shannan Hatch Joins Nikki Mitchell Foundation Board Wednesday, 30, Mar
  • Your Dollars at Work Thursday, 27, Jan
  • 2021 Impact Report Monday, 24, Jan
  • 2021 Nikki Mitchell Foundation Seed Grant Winner Monday, 22, Nov
  • A Surviving Story Thursday, 17, Jun

Contact Us

1-615-982-6802
PO Box 68305 Nashville, TN 37206
[email protected]
EIN Tax ID: 46-3399632

Join Our Mailing List

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Nikki Mitchell Foundation, PO Box 68305, Nashville, TN, 37206, http://www.nikkimitchellfoundation.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Follow Us

Contact Us

1-615-982-6802
PO Box 68305 Nashville, TN 37206
[email protected]
EIN Tax ID: 46-3399632
Copyright ©2020 Nikki Mitchell Foundation. All Rights Reserved. Nikki Mitchell Foundation is a registered 501(c)(3) non-profit.

Medical Disclaimer:
Information is solely intended as educational purpose only. It is not to be considered as a substitute for professional medical advice. We encourage all visitors to consult directly with their physician. Site visitors should not rely on any information contained for health needs. Instead, all questions should be discussed with professional medical doctors.
SearchPostsLogin
Wednesday, 30, Mar
Music Leader Shannan Hatch Joins Nikki Mitchell Foundation Board
Thursday, 27, Jan
Your Dollars at Work
Monday, 24, Jan
2021 Impact Report
Monday, 22, Nov
2021 Nikki Mitchell Foundation Seed Grant Winner
Thursday, 17, Jun
A Surviving Story
Monday, 24, May
Clinical Trials

Welcome back,